The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Oligometastatic vs oligoremnant disease
Puneeth Iyengar, MD, PhD, UT Southwestern Medical Center, Dallas, TX, provides an overview of oligometastic versus oligoremnant disease and discusses the treatment of each metastatic disease state with local therapies. Oligometastatic disease represents a clinical state of metastatic disease that is limited in the number of metastatic sites and may benefit from local consolidation therapy, whereas oligoremnant disease defines an induced oligometastatic state where a former polymetastatic disease responded to initial systemic therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
